Source: Virtual Congress 2021 – Advances in asthma treatment



Rating:

Share or cite this content

Citations should be made in the following way:
D. Attar (London, United Kingdom), T. Capstick (Leeds, United Kingdom), D. Leese (Sheffield, United Kingdom), S. Arnetorp (Gothenburg, Sweden), E. Rapsomaniki (Cambridge, United Kingdom), K. Da Costa (Cambridge, United Kingdom), Y. Xu (Cambridge, United Kingdom), J. Quint (London, United Kingdom). Healthcare costs associated with short-acting ß2-agonist use in asthma: an observational UK study from the SABINA global programme. 3525

Member's Comments

No comment yet.

Related content which might interest you: Healthcare utilization and cost associated with chronic cough in the United Kingdom: a retrospective observational study Source: Virtual Congress 2020 – New and integrated tools for respiratory diagnosis and care Year: 2020 An electronic alert to reduce excessive prescribing of short-acting beta2-agonists for people with asthma in East London: a retrospective case-control study using routine primary care data Source: Virtual Congress 2020 – Digital health interventions in respiratory medicine Year: 2020 Healthcare resource consumption in Italian patients with COPD: The MISTRAL study Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018 Asthma severity, poor control, co-morbidities and prior resource use determined omalizumab prescriptions in a nested case-control study with US claims data Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms Year: 2015 DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD (SPRINT) Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018 Change in asthma management recommendations is associated with reduction of reliever drugs in the real-world setting: a longitudinal retrospective claims data analysis in Burgenland Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Estimating potential cost savings associated with managing COPD according to GOLD 2017 recommendations in UK primary care: a CPRD study Source: International Congress 2018 – COPD management Year: 2018 Dispensed asthma therapy and medical resource utilisation in asthma patients: results from the L777 observational study Source: Annual Congress 2009 - Epidemiology of asthma Year: 2009 IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021 Randomized, controlled study of the impact of a mobile health tool on asthma SABA use, control and adherence Source: International Congress 2016 – Non-inflammatory assessment of airway disorders Year: 2016 SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß2-agonist use in asthma Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019 Year: 2020 Patterns of risk of death and asthma-related adverse outcomes in adult asthma patients receiving long-acting β2-agonist (LABA) therapy: results from the UK general practice research database (GPRD) Source: Annual Congress 2009 - Asthma treatment and control strategies in primary care Year: 2009 REG study: Real-life, longitudinal ICS adherence patterns in a UK asthma population Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Medication use and disease control of asthma patients in Flanders: a cross-sectional community pharmacy study Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005 Health resource utilisation due to IPF exacerbations in Spain: prospective, observational, multicentric study (OASIS study) Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Multi-centre research: The experience of a UK, Danish and Dutch qualitative study exploring the meaning of COPD and its exacerbations to patients Source: Eur Respir J 2003; 22: Suppl. 45, 66s Year: 2003 Overuse of short-acting ß2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme Source: Eur Respir J, 55 (4) 1901872; 10.1183/13993003.01872-2019 Year: 2020 Drug therapy of childhood asthma: results of a community-based survey in Germany Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001 Astro-Lab project: Assessment of the safety of long-acting beta agonists (LABAs) in asthma by combining health-care databases and direct patient follow-up: Description of the patient pattern in France and in the United-Kingdom (UK) Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013